Neuroblastoma is one of the major challenges of paediatric oncology. In particular the grim prognosis of patients older than 1 year with disseminated disease (about a half of all neuroblastomas) continues to stimulate the search for new treatment strategies. The high chemosensitivity of this neoplasm and the demonstrated dose-response relationship for several active agents provide the rationale for the use of on haematopoietic growth factors to support the growing aggressiveness and toxicity of modern treatment schedules. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor were initially used to accelerate the haematopoietic recovery after conventional chemotherapy and bone marrow transplantation, the aim being to reduce the incidence of neutropenic fever and infection. Their ability to allow a further increase of dose intensity of treatment and to stimulate the mobilisation of haematopoietic progenitor cells into peripheral blood was subsequently investigated. Another field of interest was directed towards the stimulation of the host immune system against residual disease by means of biological response modifiers. For instance, interferons, either alone or in combination with other molecules, have shown a remarkable anti-tumour activity in neuroblastoma cell lines and in animal models. However, the clinical value of their use requires further investigation.
|Number of pages||11|
|Journal||FORUM - Trends in Experimental and Clinical Medicine|
|Publication status||Published - 1994|
- Colony-stimulating factor
ASJC Scopus subject areas